NEW YORK, June 23 (Reuters) - Shares of Molecular Insight Pharmaceuticals Inc rose 11 percent to $1.77 in extended trading on Wednesday after the company reported positive data from a mid-stage trial of its experimental drug to treat neuroblastoma.
For details, see
(Reporting by Ryan Vlastelica) Keywords: MARKETS STOCKS AFTERTHEBELL (ryan.vlastelica@thomsonreuters.com; Tel: +1 646-223-6014; Reuters Messaging: ryan.vlastelica@reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
For details, see
(Reporting by Ryan Vlastelica) Keywords: MARKETS STOCKS AFTERTHEBELL (ryan.vlastelica@thomsonreuters.com; Tel: +1 646-223-6014; Reuters Messaging: ryan.vlastelica@reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.